Iterum Therapeutics, which is developing oral and IV antibiotics for drug-resistant bacterial infections, raised $80 million by offering 6.15 million shares at $13, below the range of $14 to $16. It had planned to offer 5.3 million shares, so with the...read more
Led by digital lending platform GreenSky and global merchant acquirer EVO Payments, eight companies are scheduled to raise a combined $1.3 billion in the week ahead. GreenSky and EVO are joined by three biotechs, a bioprosthetic device company and two small...read more
Iterum Therapeutics, which is developing oral and IV antibiotics for drug-resistant bacterial infections, announced terms for its IPO on Wednesday. The Dublin, Ireland-based company plans to raise $80 million by offering 5.3 million shares at a price range...read more
US IPO Weekly Recap: Payment IPOs pay off as 6 deals price ahead of Memorial Day
This week's highlights: 6 IPOs, including 3 biotechs and 2 payment firms, raised $1.4...read more
Iterum Therapeutics prices IPO below the range at $13
Iterum Therapeutics, which is developing oral and IV antibiotics for drug-resistant bacterial infections, raised $80 million by offering 6.15 million shares at $13, below the range of $14 to $16. It had planned to offer 5.3 million shares, so with the...read more
US IPO Week Ahead: GreenSky and EVO Payments lead 8-IPO week
Led by digital lending platform GreenSky and global merchant acquirer EVO Payments, eight companies are scheduled to raise a combined $1.3 billion in the week ahead. GreenSky and EVO are joined by three biotechs, a bioprosthetic device company and two small...read more
Antibiotics biotech Iterum Therapeutics sets terms for $80 million IPO
Iterum Therapeutics, which is developing oral and IV antibiotics for drug-resistant bacterial infections, announced terms for its IPO on Wednesday. The Dublin, Ireland-based company plans to raise $80 million by offering 5.3 million shares at a price range...read more